We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App

Ultra-Fast COVID-19 PCR Test to Achieve High Accuracy at Speed 20 Times Faster than Lab-Based PCR Tests

By LabMedica International staff writers
Posted on 22 Nov 2021
Print article
Image: MolDx Analyzer (Photo courtesy of miDIAGNOSTICS)
Image: MolDx Analyzer (Photo courtesy of miDIAGNOSTICS)

An ultra-fast COVID-19 PCR test developed for point-of-care use combines the accuracy of central lab-based PCR testing with the speed of self-testing.

miDIAGNOSTICS (Leuven, Belgium) has developed a rapid COVID-19 PCR test that has the potential to achieve an excellent accuracy at a speed 20 times faster than ‘classic’ PCR machines in labs. The test, based on the company’s highly innovative diagnostics platform, involves the transfer of a nasopharyngeal swab sample on a PCR test card, from which the results are read by a compact reader.

The COVID-19 pandemic has underscored the importance of abundant and accurate diagnostics. It will still take quite some time before herd immunity will be achieved worldwide, and ongoing virus mutations and new variants pose major challenges to the vaccination process. Meanwhile, there is a great need for rapid accurate tests that can be performed at airports, in the workplace, at events, in doctors’ offices, or even at home. Unfortunately, rapid COVID-19 tests often have limited accuracy, while reliable diagnostic tests, based on PCR analysis and performed in central laboratories, can take anywhere from several hours to several days from a sample collection to a test result.

Enabled by miDIAGNOSTICS’ silicon chip technology, its ultra-fast PCR COVID-19 test combines the speed of a rapid antigen test with the performance of trusted PCR-based testing. The company’s ultra-fast COVID-19 PCR test will take 15 minutes from sample to result. Testing can be easily scaled up with the combination of multiple readers, because of the short turnaround time of 15 minutes, enabling simultaneous high throughput in many decentralized settings where highly accurate testing is desired, including at airports, offices, schools, events or any other local healthcare setting. Beyond COVID-19, the platform has the potential to be reconfigured for diagnosing other infectious diseases, as needed.

Related Links:

Gold Supplier
Benchtop Auto Sample Transfer Processor
Undercounter Laboratory Refrigerator
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
Bench-Top Molecular Microarray System
NanoCHIP XL Analyzer

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases

The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.